Pablo Tebas is an Infectious Disease physician. ClinicalTrials.gov lists 22 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3400 Spruce St
Philadelphia, PA 191044206
Telephone
215-662-6932Registry record last updated 5 Nov 2012.
Clinical trials
- A Study of INO-A002 in Healthy Dengue Virus-naive Adults
Sponsor: University of Pennsylvania
- Oritavancin for Staphylococcus Aureus Infections in Opioid Users
Sponsor: University of Pennsylvania
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
6 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ViiV Healthcare CompanyProgram year20254 payments
- Shionogi IncProgram year20252 payments
- ViiV Healthcare CompanyProgram year202430 payments$26,315openpaymentsdata.cms.gov ↗
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
77.6%Human Immunodeficiency Virus Nucleoside Analog Reverse Transcriptase Inhibitor17.2%Descovy49%Emtricitabine-Tenofovir Disop26%Triumeq25%Part D<11 patientsHuman Immunodeficiency Virus Integrase Strand Transfer Inhibitor15.8%Tivicay86%Isentress14%Part D<11 patients+ 10 more classes in this area
Cardiovascular
11.3%Statin5.7%Rosuvastatin Calcium64%Atorvastatin Calcium36%Part D<11 patientsCalcium channel blocker3.6%Amlodipine Besylate100%Part D<11 patients+ 1 more class in this area
Nervous system
9.2%SSRI2.8%Trazodone Hcl100%Part D<11 patientsOpioid Agonist2.3%Oxycodone Hcl100%Part D<11 patients+ 2 more classes in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
6 NIH research awards on record, funded 2003–2026 per NIH RePORTER. The latest:
- University of Pennsylvania HIV Clinical Trials Unit
University of Pennsylvania
FY2026$2,830,682UM1AI069534 - University of Pennsylvania HIV Clinical Trials Unit
University of Pennsylvania
FY2025$2,761,412UM1AI069534 - University of Pennsylvania HIV Clinical Trials Unit
University of Pennsylvania
FY2024$2,946,326UM1AI069534
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Yousef Khader
Jordan University of Science and Technology
Andrew Rambaut
University of Edinburgh
Olayinka Stephen Ilesanmi
University College Hospital
Maysaa El Sayed Zaki
Mansoura University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”